東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Biomarkers of Response to Immune Che...

Panda, Anshuman.

FindBook

Google Book

Amazon

博客來

Biomarkers of Response to Immune Checkpoint Therapy.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Biomarkers of Response to Immune Checkpoint Therapy./
作者:	Panda, Anshuman.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	74 p.
附註:	Source: Dissertations Abstracts International, Volume: 79-12, Section: B.
Contained By:	Dissertations Abstracts International79-12B.
標題:	Astronomy. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10902039
ISBN:	9780438099654

Biomarkers of Response to Immune Checkpoint Therapy.
Panda, Anshuman.

Biomarkers of Response to Immune Checkpoint Therapy. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 74 p.

Source: Dissertations Abstracts International, Volume: 79-12, Section: B.

Thesis (Ph.D.)--Rutgers The State University of New Jersey, School of Graduate Studies, 2018.

This item is not available from ProQuest Dissertations & Theses.

Immune checkpoint therapy leads to durable objective response in a subset of patients with metastatic cancer in many different cancer types, but the mechanisms and biomarkers of response to immune checkpoint therapy is not fully understood. Through pan-cancer analysis of the Cancer Genome Atlas, I have so far identified 2 types of predictors of immune activation and checkpoint pathway upregulation in a total of 10 solid cancer types (skin melanoma, lung adenocarcinoma, colon, endometrial, gastric, cervical, ER+ HER2- breast, bladder, clear-cell kidney, and head-neck squamous-cell cancer): (1) hyper-mutation in tumor due to DNA proofreading defect (Chapter 2) or some other etiologies (Chapter 3), and (2) expression of exogenous (Chapter 4) or endogenous (Chapter 5) viral RNA in tumor. I also validated these predictors as biomarkers of response to immune checkpoint therapy in some of the above 10 cancer types where I had access to good quality data, using published datasets of patients treated with immune checkpoint therapy for retrospective validation, and de-identified data of patients treated with immune checkpoint therapy at the Rutgers Cancer Institute of New Jersey and the Vanderbilt Ingram Cancer Center for prospective validation.

ISBN: 9780438099654Subjects--Topical Terms:

517668
Astronomy.
Subjects--Index Terms:

Biomarkers of response

Biomarkers of Response to Immune Checkpoint Therapy.
LDR:02670nmm a2200397 4500 001 2267581
005 20200724103004.5
008 220629s2018 ||||||||||||||||| ||eng d
020 $a 9780438099654
035 $a (MiAaPQ)AAI10902039
035 $a (MiAaPQ)rutgersnb:8667
035 $a AAI10902039
040 $a MiAaPQ $c MiAaPQ
100 1 $a Panda, Anshuman. $3 3544837
245 1 0 $a Biomarkers of Response to Immune Checkpoint Therapy.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 74 p.
500 $a Source: Dissertations Abstracts International, Volume: 79-12, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
502 $a Thesis (Ph.D.)--Rutgers The State University of New Jersey, School of Graduate Studies, 2018.
506 $a This item is not available from ProQuest Dissertations & Theses.
506 $a This item must not be sold to any third party vendors.
506 $a This item must not be added to any third party search indexes.
520 $a Immune checkpoint therapy leads to durable objective response in a subset of patients with metastatic cancer in many different cancer types, but the mechanisms and biomarkers of response to immune checkpoint therapy is not fully understood. Through pan-cancer analysis of the Cancer Genome Atlas, I have so far identified 2 types of predictors of immune activation and checkpoint pathway upregulation in a total of 10 solid cancer types (skin melanoma, lung adenocarcinoma, colon, endometrial, gastric, cervical, ER+ HER2- breast, bladder, clear-cell kidney, and head-neck squamous-cell cancer): (1) hyper-mutation in tumor due to DNA proofreading defect (Chapter 2) or some other etiologies (Chapter 3), and (2) expression of exogenous (Chapter 4) or endogenous (Chapter 5) viral RNA in tumor. I also validated these predictors as biomarkers of response to immune checkpoint therapy in some of the above 10 cancer types where I had access to good quality data, using published datasets of patients treated with immune checkpoint therapy for retrospective validation, and de-identified data of patients treated with immune checkpoint therapy at the Rutgers Cancer Institute of New Jersey and the Vanderbilt Ingram Cancer Center for prospective validation.
590 $a School code: 0190.
650 4 $a Astronomy. $3 517668
653 $a Biomarkers of response
653 $a Ctla-4 blockade
653 $a Hyper-mutation in tumor
653 $a Immune checkpoint therapy
653 $a Pd-1 blockade
653 $a Viral expression in tumor
690 $a 0606
710 2 $a Rutgers The State University of New Jersey, School of Graduate Studies. $b Physics and Astronomy. $3 3544838
773 0 $t Dissertations Abstracts International $g 79-12B.
790 $a 0190
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10902039